At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions
In Brief
A Phase 1 clinical trial evaluating Quinine Sulfate Capsules 324 mg and Quinine Sulphate Tablets 300 mg for Healthy. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate and compare the relative bioavailability of Quinine Sulfate 324 mg capsules, manufactured by the Mutual Pharmaceutical Company, to Quinine Sulphate 300 mg tablets, manufactured by the Government Pharmaceutical Organization, Bangkok Metropolis, Thailand, after single oral dose administration under fasting conditions. An additional purpose of this study is to evaluate the effect of food on the Mutual Pharmaceutical Company product.
Study Details
Timeline
Interventions
One 324 mg capsule administered after an overnight fast of at least 10 hours.
One 300 mg tablet administered after an overnight fast of at least 10 hours.
One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.